Opinion|Videos|January 12, 2026
SUMMIT Trial: Key Data for Bezuclastinib in Non-Advanced Systemic Mastocytosis
Author(s)Lindsay Rein, MD, Frederick Lansigan, MD
Lindsay Rein, MD, and Frederick Lansigan, MD, discuss data from the SUMMIT trial for bezuclastinib in non-advanced systemic mastocytosis.
Advertisement
Episodes in this series
Lindsay Rein, MD, and Frederick Lansigan, MD, review key efficacy and safety data from the SUMMIT trial evaluating bezuclastinib (CGT9486) in patients with non-advanced systemic mastocytosis. They highlight improvements in symptom burden, mast cell activity, and relevant clinical endpoints. Rein and Lansigan discuss how these findings contribute to the growing evidence base supporting targeted KIT inhibition.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The selective BCR::ABL1 inhibitor ELVN-001 produced major molecular responses in previously treated chronic-phase CML, including after asciminib progression.
Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.
Revumenib added to intensive chemotherapy produced deep, MRD-negative remissions with a manageable safety profile in newly diagnosed AML.
Ofirnoflast produced hematologic improvement in two-thirds of patients with ESA-refractory lower-risk MDS.
Mayo Clinic researchers identified a potential new approach to treating glioblastoma to improve the effectiveness of existing chemotherapy.
In the phase 2 RESTORE-PV trial, DISC-3405 cut phlebotomy events and maintained hematocrit below 45% in patients with polycythemia vera.
Selcodebart improved hemoglobin levels and transfusion independence across 3 anemia cohorts in myelofibrosis, regardless of concomitant JAK inhibitor use.
Advertisement
Advertisement
Trending on OncLive
1
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
2
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
3
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
4
DISC-3405 Reduces Phlebotomy Events and Controls Hematocrit in Polycythemia Vera
5